Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 4

recruiting
3 979
countries
28
conditions
2 106

62 trials match your criteria

Pancreatic carcinoma

Not yet recruiting

Study of perioperative versus post-surgery FOLFIRINOX (irinotecan, oxaliplatin, fluorouracil, and folinic acid) treatment in patients with resectable pancreatic cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil

Ductal adenocarcinoma of pancreas

Not yet recruiting

Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil

Ductal adenocarcinoma of pancreas

Not yet recruiting

Study Comparing Short-Course and Long-Course Chemotherapy with mFOLFIRINOX or PAXG for Patients with Stage I-III Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Capecitabine

Colorectal cancer+1

Not yet recruiting

Study on Irinotecan and mFOLFOX4-Bevacizumab for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Gastric cancer+1

Not recruiting

Study on the Effectiveness and Safety of AZD0901 Compared to Standard Treatments for Adults with Advanced Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901

Neuroendocrine carcinoma

Not recruiting

Study of tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil

Colorectal cancer

Not recruiting

Study on the Safety and Effectiveness of Volrustomig with FOLFIRI and Bevacizumab for Colorectal Cancer Patients Without Liver Metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Colon cancer stage III+1

Not recruiting

Study on the Effect of Intensive Chemotherapy with FOLFOXIRI Compared to Standard Treatment for Patients with Localized Colon Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Pancreatic carcinoma

Not recruiting

Study on the Effectiveness of Laparoscopic Electrochemotherapy with Bleomycin Sulfate for Patients with Locally Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate

Colorectal adenocarcinoma

Not recruiting

Study on Chemotherapy with Irinotecan, Folinic Acid, Fluorouracil, Oxaliplatin, and Floxuridine for Patients with Colorectal Cancer Spread to the Liver

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Floxuridine

Pancreatic carcinoma+1

Not recruiting

Study on Dostarlimab, Vitamin D3, and Drug Combination for Untreated Metastatic Pancreatic Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Colecalciferol

Neuroblastoma+1

Not recruiting

Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Palbociclib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.